Synonym
CVN424; CVN 424; CVN-424; Solangepras
IUPAC/Chemical Name
(R)-2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-6-(prop-1-en-2-yl)-N-(tetrahydrofuran-3-yl)-5,6,7,8-tetrahydropyrido[3,4-b]pyrazin-3-amine
InChi Key
OJQWTBAKFUKZFP-GOSISDBHSA-N
InChi Code
InChI=1S/C25H31F2N5O2/c1-16(2)32-11-7-21-22(14-32)29-24(28-18-8-12-33-15-18)25(30-21)31-9-5-19(6-10-31)34-23-4-3-17(26)13-20(23)27/h3-4,13,18-19H,1,5-12,14-15H2,2H3,(H,28,29)/t18-/m1/s1
SMILES Code
FC1=C(OC2CCN(C3=NC4=C(CN(C(C)=C)CC4)N=C3N[C@H]5COCC5)CC2)C=CC(F)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
471.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sun H, Monenschein H, Schiffer HH, Reichard HA, Kikuchi S, Hopkins M, Macklin TK, Hitchcock S, Adams M, Green J, Brown J, Murphy ST, Kaushal N, Collia DR, Moore S, Ray WJ, Carlton MBL, Brice NL. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J Med Chem. 2021 Apr 16. doi: 10.1021/acs.jmedchem.0c02081. Epub ahead of print. PMID: 33861086.
2: Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, Xu X, Cheung T, Burley JR, Sun H, Dickson L, Murphy ST, Kaushal N, Sheardown S, Lawrence J, Chen Y, Bartkowski D, Kanta A, Russo J, Hosea N, Dawson LA, Hitchcock SH, Carlton MB. Development of CVN424: a selective and novel GPR6 inverse agonist effective in models of Parkinson's Disease. J Pharmacol Exp Ther. 2021 Apr 1:JPET-AR-2020-000438. doi: 10.1124/jpet.120.000438. Epub ahead of print. PMID: 33795395.
